Navigation Links
European Society for Medical Oncology (ESMO) Presents Data from the,Clinical Trial of MediGene's Cancer-Killing Virus in Press,Conference

* Presentation of efficacy trends from ongoing phase I/II trial of oncolytic HSV * Poster selected by ESMO for presentation in press conference

MARTINSRIED, Germany, June 29, 2007.--The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announces that a case report from the ongoing clinical trial of MediGene's cancer killing virus will be presented in a press conference held by the European Society for Medical Oncology. Out of more than 300 posters accepted for the conference, only five were chosen for presentation in the press conference.

The event will take place on Friday, July 6, at 12:30 MEST at the ESMO conference in Lugano, Switzerland (ECLU). Dr. Axel Mescheder, Head of Clinical Research and Development at MediGene, will present the data in the press conference as well as in a poster presentation during the conference.

The phase I/II trial of NV1020 for the treatment of liver metastases of colorectal cancer is being conducted at seven leading cancer centers in the US. In September 2006, MediGene announced positive safety and efficacy data from an interim analysis of this study. The poster presented at the ESMO conference shows efficacy data in a case study for the first time.

Dr. Ulrich Delvos, Chief Operating Officer of MediGene, comments. "We are delighted and proud that the European Society for Medical Oncology has decided to present a case study from our trial in a press conference. Considering the number of studies presented on Europe's largest cancer congress, this emphasizes the innovation and the potential of this approach to fight cancer."

Journalists interested in joining the press conference please contact media@esmo.org

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgmen
'"/>




Page: 1 2

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
5. Malvern initiates European user group meetings for chemical imaging
6. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
7. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. Inspire Announces Presentations at Two European Scientific Conferences
10. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
11. Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress
Post Your Comments:
(Date:10/10/2008)... WALTHAM, Mass., Oct. 10 /PRNewswire-FirstCall/...A ), a leading provider of near-patient,diagnostic... yesterday with,Ban Ki-moon, the Secretary-General...or executives of seventeen of the world,s leading,...nostic companies.,Inverness, together with senior ...
(Date:10/10/2008)... PLEASANTON, Calif., Oct. 10 /- Tr...as been authorized to affix the CE (Conformite,Eur...ntares(TM) Coronary,Stent System, a unique main ve... near coronary bifurcations., Representing the ne...(TM) system has potential use in a quarter of the ...
(Date:10/9/2008)... World Sight Day 2008 focuses on the need to pr.... 9 /- Of the 45 million people world...d three-quarters of them could,have avoided their ...reated., To view the Multimedia News Release, go ... Alcon, the world,s leader in eye care products an...
(Date:10/9/2008)... Top Line Clinical Results Expected in November...ll/ -- SCOLR Pharma, Inc.,(Amex: DDD ) announced ...ing,for the third of its three pivotal trials to e... of 12-hour extended-release (ER) ibuprofen for,th...ts to report top-line,results from this pivotal tr...
Breaking Medicine Technology:Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2ORBIS and Alcon Call Attention to the Aging Eye 2ORBIS and Alcon Call Attention to the Aging Eye 3SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board 4343 1Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board 4343 2Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board 4343 3EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 1EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 2EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 3EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 4China Bionanometer Industries 28CBIU 29 Describes their Current Production Capacity and Product Lines 15734 1China Bionanometer Industries 28CBIU 29 Describes their Current Production Capacity and Product Lines 15734 2Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 1Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 2Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 3Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 4Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 5Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 6
...TTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Scien...esults of its Phase III,AIR-CF2 study evaluating a...patients with cystic fibrosis (CF) who have,pulmon... study, a,28-day treatment course of aztreonam lys...haled or intravenous (IV) antibiotics versus,place...
...VER--(BUSINESS WIRE)--Apr 23, 2007 - Ceragenix Pha...al company focused on,infectious disease and derma...rch paper on two of the Company,s antimicrobial,co...he April issue,of the Journal of Antimicrobial Age...rnal of the American Society of,Microbiology, dedi...
Other Medicine Technology:Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 2Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 3Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 4
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
...000 worth of unapproved dietary supplements in the...e Food and Drug Administration (FDA) agency had re...age Nutraceuticals L.L.C distributed the capsules....at the seized capsules, which are supposedly in vi...
...reast cancer cases in American women appears to ha.../ that a turning point may have reached in the nat...e latest federal data it was found that after a st...cer rate stopped rising in 2001 and may have start...
...ly poetic way to describe a disease that is the fu...s father’s life and, Galvin always knew, threatene...’s sitting out on the horizon that you know one da...ays Galvin, 37. “It’s something I’ve thought about...
...d of the conjoined twins from Wisconsin has been c...ork remains ahead of them.// The lead surgeon, Ro... optimistic about the preservation of neurological...ave decided not to separate the twins' shared tail...
Other Medicine News:Health News:Plateau Reached in the Battle against Breast Cancer 2Health News:Plateau Reached in the Battle against Breast Cancer 3Health News:Deadly Lung Disease Sends Patients on ‘Quest for Breath 2Health News:Deadly Lung Disease Sends Patients on ‘Quest for Breath 3Health News:Separation of Spinal Cord of Conjoined Twins Completed Successfully 2
Gentamicin Reagent Solution (10 mg/ml) liquid
LB Agar plates with 0.1mM EDTA.
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride.
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride.
Medicine Products: